Increased urinary excretion of interleukin-17 in XXXX @entity1 .

@entity1985 @entity1 @entity4155 @entity8
BACKGROUND/AIM: @entity4155 is a newly discovered cytokine that is secreted by activated memory CD4+ T cells and modulated the early stage of immune response. To elucidate the pathophysiology of minimal-change @entity1985 (MCNS), we focused on @entity4155 , which is one of the key factors in regulating an inflammatory response, and thus determined the daily excretion of @entity4155 in urine. METHODS: For this purpose, excretion levels of @entity4155 were measured in the urine of @entity1 with MCNS during relapse and remission using a highly sensitive sandwich enzyme-linked immunosorbent assay. The data obtained were compared with levels of daily urinary excretion of @entity4155 in @entity1 with @entity8 ( @entity8 ). A group of healthy subjects served as control. In both experimental groups urine levels of @entity4155 excretion were plotted against their daily urinary protein excretion. RESULTS: We demonstrated increased levels of @entity4155 excretion in the urine of @entity1 with MCNS and @entity8 as compared to the non- @entity1985 and healthy controls. In MCNS the daily urinary @entity4155 (uIL-17) excretion was increased and returned to baseline with remission of the @entity1985 ( @entity1985 ). We also demonstrated a positive correlation between urinary protein excretion and daily uIL-17 excretion. CONCLUSION: Taken together, these data indicate that uIL-17 excretion is increased during the @entity1985 , suggesting the possibility that daily uIL-17 excretion may reflect the disease activity of @entity1985 .
